10-Q quarterly report · filed Nov 2, 2026

Neurocrine Biosciences Inc (NBIX) Q3 2026 10-Q Quarterly Report

Short answer

Neurocrine Biosciences Inc (NBIX) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.1B (up 41.2% year over year) with net income of $207M.

Q3 2026 key financials · XBRL

Revenue
$1.1B
+41.2% YoY · +17.1% QoQ
Net income
$207M
−1.4% YoY · +43.0% QoQ
Operating margin
29.5%
EPS (diluted)
$1.96
−4.9% YoY · +41.0% QoQ

Source: XBRL data from the Neurocrine Biosciences Inc (NBIX) Q3 2026 10-Q on SEC EDGAR. USD.

Neurocrine Biosciences Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Third-quarter revenue $1,122.7M, up $327.8M YoY from $794.9M
  • Operating margin 29.5% vs 30.1% YoY, net margin 18.4% vs 26.4%
  • Best product: INGREZZA sales $801.5M vs $686.6M; worst: Other sales $0 vs $5.2M
  • Cash, equivalents and securities $789.7M vs $2,543.4M; operating cash flow $677.4M for nine months
  • Soleno acquisition consumed $2.4B cash; $1.0B credit capacity available, funding sufficient for at least 12 months

Risk Factors

  • Newly added risk: VYKAT XR safety scrutiny, August 2026 advocacy warnings followed serious adverse-event reports to FDA’s AEMS
  • Most materially updated regulatory risk: FDA identified fluid retention as a potential VYKAT XR safety signal in September 2026
  • Legal and compliance risk: DOJ civil investigative demand seeks INGREZZA sales and marketing documents, received August 2025
  • Operational risk: four distribution customers represent over 90% of gross product sales, concentrating revenue exposure
  • Financial risk: $1.0 billion secured revolver entered May 2026, with variable-rate borrowings and quarterly leverage covenants

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Neurocrine Biosciences Inc quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.